Potential role of IL‐17 blocking agents in the treatment of severe COVID‐19?

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

(2020) Nanshan Chen et al.   LANCET

A new coronavirus associated with human respiratory disease in China

(2020) Fan Wu et al.   NATURE

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

(2020) Zhe Xu et al.   Lancet Respiratory Medicine

The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China

(2020) Wen Zhang et al.   CLINICAL IMMUNOLOGY

Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality

(2020) Chi Zhang et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Tocilizumab treatment in COVID-19: A single center experience

(2020) Pan Luo et al.   JOURNAL OF MEDICAL VIROLOGY

TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib

(2020) Dandan Wu et al.   JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION

Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed

(2020) Marc Feldmann et al.   LANCET

COVID-19: consider cytokine storm syndromes and immunosuppression

(2020) Puja Mehta et al.   LANCET

Elevated plasma level of selective cytokines in COVID-19 patients reflect viral load and lung injury

(2020) Yingxia Liu et al.   National Science Review

Likelihood of survival of coronavirus disease 2019

(2020) Shigui Ruan   LANCET INFECTIOUS DISEASES

Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies

(2019) José María G. Ruiz de Morales et al.   AUTOIMMUNITY REVIEWS

Psoriasis pathogenesis and the development of novel targeted immune therapies

(2017) Jason E. Hawkes et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis

(2016) K. Reich et al.   BRITISH JOURNAL OF DERMATOLOGY

Psoriasis

(2016) Jacqueline E. Greb et al.   Nature Reviews Disease Primers

IL-17 response mediates acute lung injury induced by the 2009 Pandemic Influenza A (H1N1) Virus

(2011) Chenggang Li et al.   CELL RESEARCH

IL-17 Boosts Proinflammatory Outcome of Antiviral Response in Human Cells

(2011) Grigory Ryzhakov et al.   JOURNAL OF IMMUNOLOGY

Critical Role of IL-17RA in Immunopathology of Influenza Infection

(2009) C. R. Crowe et al.   JOURNAL OF IMMUNOLOGY